Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GRCE, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| GTX-104 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | Phase 3 · NCT05995405 | Active not recruiting |
| Nimodipine | Aneurysmal Subarachnoid Hemorrhage (aSAH) | Phase 3 · NCT05995405 | Active not recruiting |
| Clonidine | Pregnancy Related | Phase 2 · NCT05487196 | Completed |
| Ropivacaine | Pregnancy Related | Phase 2 · NCT05487196 | Completed |
| GTX-101 | Postherpetic Neuralgia | Phase 1 · NCT05517486 | Unknown |
| Ketamine (Ketalar) Dose Level 1 | Pain, Postoperative | Phase 1 · NCT05907213 | Completed |
| Ketamine (Ketalar) Dose Level 2 | Pain, Postoperative | Phase 1 · NCT05907213 | Completed |
| Ketamine (Ketalar) Dose Level 3 | Pain, Postoperative | Phase 1 · NCT05907213 | Completed |
| Ketamine (Ketalar) Dose Level 4 | Pain, Postoperative | Phase 1 · NCT05907213 | Completed |
| Oxycodone | Cesarean Section Complications | N/A · NCT05280743 | Completed |
Also used in these trials (approved or third-party drugs, not GRCE's own candidates): Tirzepatide, Dexmedetomidine, Fentanyl, Bupivacaine Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GRCE holds $21.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 25.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRCE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Opaleye Management Inc. 10% owner |
Insider | 3,054,853 | 14.52% | 2026-11-03 |
| ADAR1 Capital Management, LLC 10% owner |
Insider | 2,281,877 | 10.85% | 2026-09-30 |
| ADAR1 Capital Management GP, LLC | 5%+ holder (13G) | 1,717,426 | 8.16% | 2026-03-31 |
| Nantahala Capital Management, LLC | Institution (13G, 5%+) | 1,654,393 | 7.86% | 2026-09-30 |
| Prashant Kohli Chief Executive Officer, Director · +621,330 options |
Insider | 121,357 | 0.58% | 2026-09-09 |
Share count 21,035,930 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-04-23 | GTx-104 | NDA | -2.7% | -45.5% | -51.3% |
| 2025-08-22 | — | NDA | -1.5% | -1.5% | -9.4% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRCE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →